LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI), a pioneering biotechnology firm committed to revolutionizing the treatment landscape for inflammatory, fibrotic, and autoimmune diseases, has received an exciting announcement regarding its upcoming presentation at the prestigious 2025 ATS International Conference. This significant event is scheduled to take place from May 18 to May 21, 2025, in the vibrant city of San Francisco, California.

The focus of GRI Bio's presentation will be on their innovative research detailing the inactivation of invariant Natural Killer T (iNKT) cells during the resolution phase of inflammation. Their study suggests that such inactivation might substantially inhibit fibroblast activation and consequently reduce fibrosis in models of pulmonary fibrosisan area of critical medical need.

The specifics of the poster presentation are as follows:

  • Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis
  • Poster Board Number: 810
  • Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI Bio
  • Session: D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR
  • Date and Time: Wednesday, May 21, 2025, from 8:15 AM to 10:15 AM PT
  • Location: Room 2022/2024 (West Building, Level 2), Moscone Center

Attendees of the conference are invited to explore GRI Bio's findings that could potentially alter the understanding and management of pulmonary fibrosis, a serious condition marked by lung scarring and inflammation that significantly impairs respiratory function.

For further details on the 2025 ATS International Conference, interested parties can visit the official conference website.

About GRI Bio, Inc.

GRI Bio operates at the forefront of clinical-stage biopharmaceutical innovation, with a mission of transforming how inflammatory, fibrotic, and autoimmune diseases are approached therapeutically. The companys unique therapies are meticulously designed to engage Natural Killer T (NKT) cellscritical players in the immune responseaiming to halt disease progression and restore the immune systems balance. iNKT cells are a specialized subset of T cells that exhibit characteristics of both innate and adaptive immunity, thus serving as a crucial link in the immune system's response chain.

One of GRI Bios flagship initiatives is GRI-0621, a promising oral therapy that acts as an inhibitor of iNKT cell activity, specifically targeting idiopathic pulmonary fibrosisa condition that currently presents significant treatment challenges. Additionally, GRI Bio is advancing a robust pipeline of diverse NKT (dNKT) agonists aimed at the treatment of systemic lupus erythematosus, showcasing the companys commitment to addressing unmet medical needs across a spectrum of diseases. With over 500 proprietary compounds in its repository, GRI Bio is well-positioned to sustain a progressive pipeline of novel therapies in the coming years.

Forward-Looking Statements

This press release contains forward-looking statements as defined under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by terms such as anticipate, believe, expect, and other similar expressions. Such statements reflect the companys current beliefs and expectations and include, but are not limited to, projections related to the development and commercialization of its product candidates, the timing of clinical trials, and anticipated regulatory approvals.

While GRI Bio is optimistic about these prospects, it cautions that actual results may differ due to various uncertainties and risks, including potential regulatory hurdles, market competition, and financial considerations. Investors should not rely solely on forward-looking statements as the foundation for future expectations.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com